Sandwich Assay Patents (Class 435/7.94)
-
Patent number: 8628973Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of providing a feline or canine sample, contacting the sample with at least one antibody which, when determining feline proBNP, or fragments thereof, respectively, binds to at least one epitope in the region comprising the amino acids 20 to 42 and/or in the region comprising the amino acids 57 to 80 of feline proBNP and, when determining canine proBNP, or fragments thereof, binds to at least one epitope in the region comprising the amino acids 20 to 86 of canine proBNP, and determining the presence and/or concentration of the feline or canine proBNP, or fragments thereof, present in the sample.Type: GrantFiled: September 8, 2005Date of Patent: January 14, 2014Assignee: Biomedica Medizinprodukte GmbH & Co KGInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Patent number: 8628933Abstract: The invention relates to a kit for a homogenous detection method for the quantitative or qualitative detection of an analyte in an assay and adequate reagents therefor, particularly a homogenous binding test. According to the invention, an analyte-specific binding partner R1 comprises more than one specific binding point for a specific binding partner X that is associated with a component of a signal-forming system while a second analyte-specific binding partner R2 comprises more than one specific binding point for a specific binding partner Y which is also associated with a component of a signal-forming system.Type: GrantFiled: January 23, 2013Date of Patent: January 14, 2014Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Carsten Schelp, Michael Trier, Hrair Kirakossian
-
Publication number: 20140010817Abstract: The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof.Type: ApplicationFiled: May 15, 2013Publication date: January 9, 2014Applicant: Daiichi Sankyo Company, LimitedInventor: Daiichi Sankyo Company, Limited
-
Publication number: 20140011220Abstract: The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.Type: ApplicationFiled: August 19, 2013Publication date: January 9, 2014Applicant: N-DIA, INC.Inventors: Boris Fuks, Dmitrii D. Petrunin, Evgeny I. Zaraisky, Marina N. Boltovskaya, Svetlana V. Nazimova, Nelly A. Starosvetskaya, Alexandr Konstantinov, Margarita I. Marshiskaia
-
Publication number: 20140011811Abstract: The invention provides methods relating to the diagnosis and treatment of diastolic heart failure, kits for diagnosing diastolic heart failure or diastolic dysfunction, and related systems, computer readable storage media, and methods implemented by a processor in a computer.Type: ApplicationFiled: March 15, 2013Publication date: January 9, 2014Applicants: The United States Government as represented by the Department of Veterans Affairs, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, The United States Government as represented by the Department of Veterans Affairs
-
Publication number: 20140004545Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.Type: ApplicationFiled: June 3, 2013Publication date: January 2, 2014Applicant: Biolncept, LLCInventor: Eytan R. BARNEA
-
Publication number: 20140005098Abstract: The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders.Type: ApplicationFiled: February 24, 2012Publication date: January 2, 2014Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Jean-François Godeau, Yves Le Bouc
-
Patent number: 8617826Abstract: Thyroid Stimulating Hormone (TSH) immunoassays are performed using an ELISA sandwich assay that employs scavenging or sacrificial beads for reducing interference caused by cross-reacting endocrine glycoprotein hormone analogues such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).Type: GrantFiled: November 29, 2011Date of Patent: December 31, 2013Assignee: Abbott Point of Care Inc.Inventors: Gordon Bruce Collier, John Emegbero Omakor
-
Publication number: 20130344517Abstract: Described herein are materials and methods for predicting and/or monitoring preeclampsia and related conditions, including eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, left ventricular dysfunction, and heart failure, in a pregnant or post-partum woman. More specifically, use of the endogenous protein galectin-3 in predicting and/or monitoring preeclampsia and related conditions in a pregnant or post-partum woman is described. Also described are methods of preventing and/or treating preeclampsia and related conditions by inhibiting galectin-3.Type: ApplicationFiled: January 7, 2013Publication date: December 26, 2013Applicant: BG Medicine, Inc.Inventor: Pieter Muntendam
-
Publication number: 20130344516Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ARMET in said sample in vitro.Type: ApplicationFiled: September 10, 2013Publication date: December 26, 2013Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Johann Karl, Julia Riedlinger, Markus Roessler
-
Publication number: 20130336894Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.Type: ApplicationFiled: July 22, 2013Publication date: December 19, 2013Inventor: Eric W. Olle
-
Patent number: 8609424Abstract: Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and/or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods.Type: GrantFiled: September 29, 2008Date of Patent: December 17, 2013Assignee: Advanced Life Science Institute, Inc.Inventors: Katsumi Aoyagi, Yukiji Izawa
-
Publication number: 20130330752Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Angiopoietin-related protein 3, Soluble Lymphatic vessel endothelial hyaluronic acid receptor 1, and Vascular endothelial growth factor D as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: January 27, 2012Publication date: December 12, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130330343Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.Type: ApplicationFiled: December 13, 2012Publication date: December 12, 2013Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KGInventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
-
Publication number: 20130331329Abstract: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.Type: ApplicationFiled: February 24, 2012Publication date: December 12, 2013Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John Robert Pollard, Peter B. Crino
-
Patent number: 8603828Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.Type: GrantFiled: November 8, 2010Date of Patent: December 10, 2013Assignee: Bio-Rad Laboratories, Inc.Inventors: Roger Walker, Benedicte Jardin
-
Patent number: 8592171Abstract: Embodiments described herein include methods and assays for detecting an analyte in a sample using a plurality of control zone capture agents. Some embodiments include detection of multiple analytes in a sample utilizing a plurality of analyte binders and a control zone containing multiple control zone capture agents. In some embodiments, the multiple control zone capture agents capture a plurality of binders within one control zone. Test results are determined by comparison of the control zone signal to a test zone signal.Type: GrantFiled: June 11, 2012Date of Patent: November 26, 2013Assignee: Charm Sciences, Inc.Inventors: Steven J. Saul, Robert J. Markovsky, David W. Douglas
-
Publication number: 20130309699Abstract: Embodiments herein provide methods of purifying monoclonal and polyclonal anti-bodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.Type: ApplicationFiled: January 18, 2012Publication date: November 21, 2013Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Zihni Basar Bilgicer, Tanyel Kiziltepe Bilgicer, Nathan Joseph Alves, Jonathan Darryl Ashley, Michael William Handlogten
-
Patent number: 8586322Abstract: Methods are disclosed for determining an immunosuppressant drug in a sample suspected of containing an immunosuppressant drug. The method includes providing in combination in a medium the sample, a first monoclonal antibody for the immunosuppressant drug, and a second monoclonal antibody for the immunosuppressant drug. The second monoclonal antibody binds to a portion of the immunosuppressant drug other than the portion to which the first monoclonal antibody binds to the immunosuppressant drug. The medium is incubated under conditions for binding of the first monoclonal antibody and the second monoclonal antibody to the immunosuppressant drug. The medium is examined for the presence of an immunocomplex comprising the immunosuppressant drug, the first monoclonal antibody and the second monoclonal antibody. The presence and/or amount of the immunocomplex indicates the presence and/or amount of the immunosuppressant drug in the sample.Type: GrantFiled: March 7, 2012Date of Patent: November 19, 2013Assignee: Siemens Healthcare Diagnostics, IncInventor: Tie Quan Wei
-
Publication number: 20130302329Abstract: The present invention provides for methods and compositions for identifying and detecting autoantigens. Candidate autoantigens are identified by obtaining a subject sample from which HLA-DR-presented peptides are collected and identified using mass spectometry, then synthesized and reacted with the same subject peripheral blood or effected tissue. In particular, the present invention provides for endothelial cell growth factor as a novel autoantigen biomarker for Lyme disease-associated arthritis.Type: ApplicationFiled: September 21, 2011Publication date: November 14, 2013Applicants: TRUSTEES OF BOSTON UNIVERSITY, THE GENERAL HOSPITAL CORPORATIONInventors: Allen C. Steere, Elise Drouin, Catherine Costello, Robert Seward
-
Publication number: 20130295594Abstract: The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated.Type: ApplicationFiled: May 1, 2012Publication date: November 7, 2013Applicants: Alba Therapeutics Corporation, University of Maryland, BaltimoreInventors: Julio Bai, Alessio Fasano, Blake Paterson, Alicia Sambueli
-
Publication number: 20130288280Abstract: Evaluation of VLP-1 levels in combination with at least one of amyloid-? peptide (A?), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.Type: ApplicationFiled: June 27, 2013Publication date: October 31, 2013Inventors: Jack H. LADENSON, Omar LATERZA, Vijay MODUR
-
Patent number: 8569001Abstract: A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.Type: GrantFiled: April 21, 2011Date of Patent: October 29, 2013Assignees: Seikagaku Corporation, Saint Louis UniversityInventors: Kazuo Okamura, Shuichi Miyaura, Shunji Tomatsu
-
Publication number: 20130252267Abstract: Described are uses of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.Type: ApplicationFiled: May 24, 2013Publication date: September 26, 2013Inventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
-
Publication number: 20130245038Abstract: Provided herein is a method for detecting an HPA axis function marker in a biological sample. The method may be used to determine whether a patient is a suitable candidate for treatment with a V1B antagonist. The HPA marker may be a genomic marker, non-genomic marker, or a combination thereof. Depending on the type of HPA marker, the method of detection can be an immunoassay or genotyping, for example.Type: ApplicationFiled: March 13, 2013Publication date: September 19, 2013Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KGInventors: David Katz, Marcel van Gaalen
-
Publication number: 20130243757Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.Type: ApplicationFiled: March 4, 2013Publication date: September 19, 2013Applicants: Protgen Ltd., Tsinghua UniversityInventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
-
Publication number: 20130236918Abstract: Methods are disclosed for determining an immunosuppressant drug in a sample suspected of containing an immunosuppressant drug. The method includes providing in combination in a medium the sample, a first monoclonal antibody for the immunosuppressant drug, and a second monoclonal antibody for the immunosuppressant drug. The second monoclonal antibody binds to a portion of the immunosuppressant drug other than the portion to which the first monoclonal antibody binds to the immunosuppressant drug. The medium is incubated under conditions for binding of the first monoclonal antibody and the second monoclonal antibody to the immunosuppressant drug. The medium is examined for the presence of an immunocomplex comprising the immunosuppressant drug, the first monoclonal antibody and the second monoclonal antibody. The presence and/or amount of the immunocomplex indicates the presence and/or amount of the immunosuppressant drug in the sample.Type: ApplicationFiled: March 7, 2012Publication date: September 12, 2013Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventor: Tie Quan Wei
-
Publication number: 20130236919Abstract: The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated or reduced levels of A? protein, including A?1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a major or minor depressive episode/disorder attributed to elevated or reduced levels of A? protein, including A?1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF as well as in the brain. The invention also relates to the treatment of these disorders by administering an agent that either prevents production of A?, prevents aggregation of A? fibrils, or that increases the degradation or clearance of A?. In addition, the invention provides a method of treating or preventing a major or minor depressive disorder by administering an agent that prevents or interferes with A?-induced neurotoxicity.Type: ApplicationFiled: February 27, 2013Publication date: September 12, 2013Applicant: New York UniversityInventor: Nunzio Pomara
-
Publication number: 20130230871Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Interleukin-5, Interleukin-6 receptor subunit beta, Tissue factor, Sex hormone-binding globulin, Alpha-2-macroglobulin, Apolipoprotein A-I, Calcitonin, Thrombopoietin, C-reactive protein, Intercellular adhesion molecule 3, Macrophage metalloelastase, Apolipoprotein B-100, and Fibrinogen as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: February 4, 2011Publication date: September 5, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130224776Abstract: The invention provides isolated anti-PCan065 antibodies that bind to PCan065. The invention also encompasses compositions comprising an anti-PCan065 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PCan065 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-PCan065 antibodies. The invention encompasses a method of producing the anti-PCan065 antibodies. Other aspects of the invention are a method of killing an PCan065-expressing cancer cell, comprising contacting the cancer cell with an anti-PCan065 antibody and a method of alleviating or treating an PCan065-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-PCan065 antibody to the mammal.Type: ApplicationFiled: May 8, 2012Publication date: August 29, 2013Applicant: DIADEXUS, INC.Inventors: RONG A. FAN, KIRSTIN L. KRALL
-
Patent number: 8518653Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.Type: GrantFiled: June 5, 2009Date of Patent: August 27, 2013Assignee: Teknologian Tutkimuskeskus VTTInventors: Kristiina Takkinen, Hans Söderlund, Timo Pulli
-
Publication number: 20130217050Abstract: Provided are an agent for noninvasively and easily diagnosing Alzheimer's disease, a method for diagnosing Alzheimer's disease through the measurement, and a measurement kit therefor. The present invention relates to a reagent for measuring soluble GPVI (sGPVI) in a human body fluid; an agent for specifically diagnosing Alzheimer's disease, said agent comprising a reagent for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid; and a method for specifically diagnosing Alzheimer's disease, said method comprising a step for measuring the concentration of sGPVI in a collected human body fluid and a step for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid.Type: ApplicationFiled: September 6, 2011Publication date: August 22, 2013Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Katsuki Naitoh, Yoshitaka Hosaka
-
Publication number: 20130217049Abstract: Disclosed herein are methods and systems for the detection of an analyte of interest by an amplified assay. The method and systems of the invention utilize the high specificity of biomolecules that have been coupled to a solid support to further amplify a signal produced by the interaction of a binding agent with the analyte of interest as a means to detect low levels of the analyte of interest present in a sample. In certain embodiments, for immunochemical (for example, ELISA or RIA) or immunofluorescence assays in which a protein to be identified is bound directly or through capture antibodies to a passivated surface, amplification of ˜10,000-fold can be achieved.Type: ApplicationFiled: February 21, 2013Publication date: August 22, 2013Applicant: Laboratory Corporation of America HoldingsInventor: Laboratory Corporation of America Holdings
-
Publication number: 20130210041Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: February 26, 2011Publication date: August 15, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130210043Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: June 23, 2011Publication date: August 15, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130210042Abstract: The present invention relates to a method for the diagnosis and/or prognosis of tauopathies, in particular Alzeimer's disease. The method is based on the detection and quantification of a 20-22 kDa NH2-tau fragment.Type: ApplicationFiled: June 3, 2011Publication date: August 15, 2013Applicant: CONSIGLIO NAZIONALE DELLE RICERCHEInventors: Giuseppina Amadoro, Pietro Calissano, Veronica Corsetti
-
Patent number: 8507214Abstract: The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride.Type: GrantFiled: September 27, 2008Date of Patent: August 13, 2013Assignee: Beijing Kwinbon Biotechnology Co., Ltd.Inventors: Fangyang He, Yuping Wan, Caiwei Feng, Zhengmiao Zhao, Caimao Feng, Shanliang Wang, Xiaoqin Luo, Xiaobin Ma
-
Publication number: 20130203612Abstract: The present invention relates to a reliable method of prediction of sepsis in humans after a trauma, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development of sepsis at early stages of the disease. Furthermore a method of determination of PSP/reg levels in serum is described.Type: ApplicationFiled: March 29, 2013Publication date: August 8, 2013Applicant: UNIVERSITAET ZUERICHInventors: Rolf Graf, Daniel Bimmler, Marius Keel
-
Publication number: 20130203074Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.Type: ApplicationFiled: June 23, 2011Publication date: August 8, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130203616Abstract: Methods and kits for detecting antibodies (e.g., anti-drug antibodies) specific for abundant body fluid components are provided. Such methods and kits permit the detection of, for example, human serum albumin in human body fluids, such as blood, plasma and serum.Type: ApplicationFiled: April 26, 2011Publication date: August 8, 2013Applicant: MERRIMACK PHARMACEUTICALSInventors: Sam Shenghua Song, Arthur J. Kudla, Mark David Moody
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Patent number: 8497136Abstract: A device and method for detecting the presence of hemoglobin in a biological sample, more particularly, the presence of blood in a fecal sample as an indicator of upper or lower gastrointestinal tract bleeding.Type: GrantFiled: May 29, 2012Date of Patent: July 30, 2013Assignee: Quest Diagnostics Investments IncorporatedInventor: Howard Milne Chandler
-
Patent number: 8497138Abstract: In one aspect the present invention provides a method for selecting a cell or cell colony which produces a polypeptide of interest, comprising a) providing a medium comprising cells and a detection agent, wherein the detection agent is associated with a detectable signal and the detection agent is capable of binding to the polypeptide of interest; b) providing a solid phase having a capture agent disposed thereon, wherein the capture agent is capable of binding to the polypeptide of interest; c) contacting the medium with the solid phase; d) detecting the signal associated with the detection agent; and e) selecting a cell or cell colony associated with the signal, wherein presence of the signal is indicative of a cell or cell colony which produces the polypeptide of interest.Type: GrantFiled: September 30, 2010Date of Patent: July 30, 2013Assignee: Genetix LimitedInventors: Julian Burke, Alasdair Robertson, Xiao Zhang
-
Patent number: 8492167Abstract: Methods and apparatuses for determining whether a fluid has been introduced into an assay measurement apparatus involving delivering a fluid to a surface of a resonant device. The methods also involve monitoring an electrical signal output by the resonant device, wherein properties of the electrical signal vary based on physical properties of the fluid in contact with the surface of the resonant device and determining if the electrical signal output by the resonant device satisfies a predetermined condition indicative of the presence of the fluid.Type: GrantFiled: November 21, 2006Date of Patent: July 23, 2013Assignee: BioScale, Inc.Inventors: Brett P. Masters, Michael F. Miller
-
Patent number: 8492107Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.Type: GrantFiled: June 24, 2010Date of Patent: July 23, 2013Assignees: University of Florida Research Foundation, Inc., Banyan Biomarkers, Inc.Inventors: Ka-Wang (Kevin) Wang, Ming-Cheng Liu, Monika Oli
-
Publication number: 20130183278Abstract: The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD as opposed to another neurodegenerative disease. The method of the invention comprises measuring the concentration of ?-synuclein (?-syn) and the concentration of unphosphorylated tau (tau) and/or phosphorylated tau (p-tau) in a cerebrospinal fluid sample taken from an individual. The method also comprises calculating the ratio of the concentration of tau and/or p-tau to the concentration of ?-syn, and thereby determining whether or not the individual has PD.Type: ApplicationFiled: July 6, 2011Publication date: July 18, 2013Applicant: United Arab Emirates UniversityInventors: Omar El-Agnaf, Lucilla Parnetti, Paolo Calabresi
-
Publication number: 20130183698Abstract: A membrane-based assay device, methods and kits for determining the presence or quantity of an analyte in a test sample are provided. The immunochromatographic device comprises a membrane having a capture antibody bound thereto at a test zone, wherein the capture antibody is capable of binding with an analyte, in particular a Z-AAT protein present in a sample from a PiZ gene carrier.Type: ApplicationFiled: September 23, 2011Publication date: July 18, 2013Inventor: Marco Grebe
-
Patent number: 8486721Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.Type: GrantFiled: July 27, 2012Date of Patent: July 16, 2013Assignee: Abbott Point of Care Inc.Inventors: John Lewis Emerson Campbell, Graham Davis
-
Publication number: 20130177923Abstract: Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.Type: ApplicationFiled: February 28, 2013Publication date: July 11, 2013Applicant: BioPorto Diagnostics A/SInventor: BioPorto Diagnostics A/S
-
Publication number: 20130177567Abstract: Provided are antibodies directed against a novel epitope on the human C3c (complement factor 3 c) and the use and manufacture thereof. Moreover, there is provided a novel immunogen for use in the preparation of the antibodies. The antibodies are in the first place of the monoclonal type.Type: ApplicationFiled: May 17, 2011Publication date: July 11, 2013Applicant: Sydansk UniversitetInventors: Mikkel Ole Skjoedt, Lars Vitved, Yaseelan Palarasah